Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.49 |
| ▸ | EPOR | P19235 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387250 | 0.93 | KMT2A (0.49) | PPARGLTA4HITGB3ITGA2BMMP9 | |
| SCHEMBL2387351 | 0.92 | ABCB1 (0.47) | PPARG | |
| SCHEMBL2388332 | 0.92 | PPARG (0.53) | PPARGLTA4HMMEACECPA1 | |
| SCHEMBL2384543 | 0.91 | GPR132 (0.52) | PPARGLTA4HMMEACECPA1 | |
| SCHEMBL2388052 | 0.90 | CTSL (0.46) | PPARGMMEACE | |
| SCHEMBL2385221 | 0.90 | PPARG (0.52) | PPARGLTA4HMMEACECPA1 | |
| SCHEMBL2386981 | 0.89 | ABCB1 (0.44) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL2386712 | 0.89 | ATM (0.49) | PPARGITGB3ITGA2B | |
| SCHEMBL2386937 | 0.88 | MEN1 (0.44) | PPARG | |
| SCHEMBL2385840 | 0.88 | ABCB1 (0.42) | PPARGMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017378-B2 | Method for production of optically active biphenylalanine compound or salt or ester thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| EP-1980622-B1 | METHOD FOR PRODUCTION OF AN OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF | SUMITOMO CHEMICAL CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090011475-A1 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1980622-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090011475-A1 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof | DNPEP, APEH, PAH | PPARG 4507/4885LTA4H 438/4885MME 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.